130 related articles for article (PubMed ID: 30905707)
21. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport.
Beukeveld GJ; In 't Veld G; Havinga R; Groen AK; Wolthers BG; Kuipers F
J Hepatol; 1996 Mar; 24(3):343-52. PubMed ID: 8778203
[TBL] [Abstract][Full Text] [Related]
22. Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.
Shen H; Dai J; Liu T; Cheng Y; Chen W; Freeden C; Zhang Y; Humphreys WG; Marathe P; Lai Y
J Pharmacol Exp Ther; 2016 May; 357(2):382-93. PubMed ID: 26907622
[TBL] [Abstract][Full Text] [Related]
23. Lithocholate cholestasis--sulfated glycolithocholate-induced intrahepatic cholestasis in rats.
Yousef IM; Tuchweber B; Vonk RJ; Massé D; Audet M; Roy CC
Gastroenterology; 1981 Feb; 80(2):233-41. PubMed ID: 7450414
[No Abstract] [Full Text] [Related]
24. Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver.
Uchida M; Tajima Y; Kakuni M; Kageyama Y; Okada T; Sakurada E; Tateno C; Hayashi R
Drug Metab Dispos; 2018 Jan; 46(1):11-19. PubMed ID: 29051147
[TBL] [Abstract][Full Text] [Related]
25. Determinants of serum bile acids in chronic liver disease.
Paré P; Hoefs JC; Ashcavai M
Gastroenterology; 1981 Nov; 81(5):959-64. PubMed ID: 7286574
[No Abstract] [Full Text] [Related]
26. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.
Barnett S; Ogungbenro K; Ménochet K; Shen H; Lai Y; Humphreys WG; Galetin A
Clin Pharmacol Ther; 2018 Sep; 104(3):564-574. PubMed ID: 29243231
[TBL] [Abstract][Full Text] [Related]
27. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.
Mori D; Kashihara Y; Yoshikado T; Kimura M; Hirota T; Matsuki S; Maeda K; Irie S; Ieiri I; Sugiyama Y; Kusuhara H
Drug Metab Pharmacokinet; 2019 Feb; 34(1):78-86. PubMed ID: 30528195
[TBL] [Abstract][Full Text] [Related]
28. Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.
Takehara I; Yoshikado T; Ishigame K; Mori D; Furihata KI; Watanabe N; Ando O; Maeda K; Sugiyama Y; Kusuhara H
Pharm Res; 2018 May; 35(7):138. PubMed ID: 29748935
[TBL] [Abstract][Full Text] [Related]
29. Bile acid sulfates. I. Synthesis of lithocholic acid sulfates and their identification in human bile.
Palmer RH; Bolt MG
J Lipid Res; 1971 Nov; 12(6):671-9. PubMed ID: 5124532
[TBL] [Abstract][Full Text] [Related]
30. The interaction of rifamycin-SV with the hepatic transport and sulfation of taurolithocolic acid in rats.
Bonazzi P; Novelli G; Galeazzi R
Pharmacol Res Commun; 1986 Aug; 18(8):675-85. PubMed ID: 3763675
[TBL] [Abstract][Full Text] [Related]
31. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
[TBL] [Abstract][Full Text] [Related]
32. Prediction of Human Disproportionate and Biliary Excreted Metabolites Using Chimeric Mice with Humanized Liver.
Kato S; Shah A; Plesescu M; Miyata Y; Bolleddula J; Chowdhury S; Zhu X
Drug Metab Dispos; 2020 Oct; 48(10):934-943. PubMed ID: 32665417
[TBL] [Abstract][Full Text] [Related]
33. Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.
Takita H; Scotcher D; Chu X; Yee KL; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2022 Sep; 112(3):615-626. PubMed ID: 35652251
[TBL] [Abstract][Full Text] [Related]
34. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
[TBL] [Abstract][Full Text] [Related]
35. Metabolism of lethocholate in healthy man. I. Biotransformation and biliary excretion of intravenously administered lithocholate, lithocholylglycine, and their sulfates.
Cowen AE; Korman MG; Hofmann AF; Cass OW
Gastroenterology; 1975 Jul; 69(1):59-66. PubMed ID: 1150035
[TBL] [Abstract][Full Text] [Related]
36. Sex differences in hepatic sulfation of taurolithocholate in the rat.
Hammerman KJ; Chen LJ; Fernandez-Corugedo A; Earnest DL
Gastroenterology; 1978 Dec; 75(6):1021-5. PubMed ID: 710853
[TBL] [Abstract][Full Text] [Related]
37. Separate transport systems for biliary secretion of sulfated and unsulfated bile acids in the rat.
Kuipers F; Enserink M; Havinga R; van der Steen AB; Hardonk MJ; Fevery J; Vonk RJ
J Clin Invest; 1988 May; 81(5):1593-9. PubMed ID: 3366909
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of sulfate esters of lithocholic acid, glycolithocholic acid, and taurolithocholic acid with sulfur trioxide-triethylamine.
Tserng KY; Klein PD
J Lipid Res; 1977 Jul; 18(4):491-5. PubMed ID: 894140
[TBL] [Abstract][Full Text] [Related]
39. Enhanced biliary excretion of lithocholate-3-sulfate by ursodeoxycholate-3,7-disulfate infusion in Eisai hyperbilirubinemic rat (EHBR).
Takikawa H; Sano N; Ogasawara T; Yamanaka M
Dig Dis Sci; 1998 Jan; 43(1):188-92. PubMed ID: 9508524
[TBL] [Abstract][Full Text] [Related]
40. The effect of taurine on the cholestatic potential of sulfated lithocholate and its conjugates.
Belli DC; Roy CC; Fournier LA; Tuchweber B; Giguère R; Yousef IM
Liver; 1991 Jun; 11(3):162-9. PubMed ID: 1886461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
